On September 11, 2007 a research paper published in the Journal of the American Medical Association (JAMA) found that patients taking Avandia had a 42% greater chance of a heart attack. The results, compiled from four separate clinical trials of Avandia lasting at least one year each, confirm earlier studies suggesting increased cardiological risks from taking Avandia.
In contrast, a separate paper also published by JAMA concluded Actos, a rival diabetes treatment from Takeda Pharmaceuticals, appeared to reduce patients’ risk of heart attacks. The studies did not compare Avandia with Actos.
